Requirement for expert histopathological assessment of ovarian cancer and borderline tumours

The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following his...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2000-02, Vol.82 (4), p.760-762
Main Authors: SENGUPTA, P. S, SHANKS, J. H, BUCKLEY, C. H, RYDER, W. D. J, DAVIES, J, REYNOLDS, K, SLADE, R. J, KITCHENER, H. C, JAYSON, G. C
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Differentiation
Disease Progression
Female
Genital system. Mammary gland
Humans
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Middle Aged
Neoplasm Staging
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Recurrence
Short Communication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c464t-3337970956f0b6c1229e5d80a9c2455855046a83ec15b684780332ac7c80f4323
cites
container_end_page 762
container_issue 4
container_start_page 760
container_title British journal of cancer
container_volume 82
creator SENGUPTA, P. S
SHANKS, J. H
BUCKLEY, C. H
RYDER, W. D. J
DAVIES, J
REYNOLDS, K
SLADE, R. J
KITCHENER, H. C
JAYSON, G. C
description The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
doi_str_mv 10.1054/bjoc.1999.0994
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>998619201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-3337970956f0b6c1229e5d80a9c2455855046a83ec15b684780332ac7c80f4323</originalsourceid><addsrcrecordid>eNpdkc9rFDEUx4NY7Fq9elOCiLdZX35NkosgRW2hIIjehJDJZrpZZpJtMlP0vzfTXWrrKYT3ycv3vQ9CrwisCQj-odsltyZa6zVozZ-gFRGMNkRR-RStAEA2oCmcouel7OpVg5LP0CkByajkZIV-ffc3c8h-9HHCfcrY_977POFtKFPa22mbhnQdnB2wLcWXcselHqdbm4ON2NnofMY2bnCX8sbnIUSPp3lMcy4v0Elvh-JfHs8z9PPL5x_nF83Vt6-X55-uGsdbPjWMMaklaNH20LWOUKq92Ciw2lEuhBICeGsV846IrlVcKmCMWiedgp4zys7Qx0Pf_dyNfuNqxmwHs89htPmPSTaYx5UYtuY63RrKJGdqafD-2CCnm9mXyYyhOD8MNvo0F1PDSSkFq-Db_8BdHTTW4UxNrRUnABVaHyCXUynZ9_dJCJjFmlmsmcWaWazVB28e5n-AHzRV4N0RsKW66HPdeij_uLoDLWTFXh-waKc5-_t62-q7f_4CRGCq3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229984100</pqid></control><display><type>article</type><title>Requirement for expert histopathological assessment of ovarian cancer and borderline tumours</title><source>PubMed Central</source><creator>SENGUPTA, P. S ; SHANKS, J. H ; BUCKLEY, C. H ; RYDER, W. D. J ; DAVIES, J ; REYNOLDS, K ; SLADE, R. J ; KITCHENER, H. C ; JAYSON, G. C</creator><creatorcontrib>SENGUPTA, P. S ; SHANKS, J. H ; BUCKLEY, C. H ; RYDER, W. D. J ; DAVIES, J ; REYNOLDS, K ; SLADE, R. J ; KITCHENER, H. C ; JAYSON, G. C</creatorcontrib><description>The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.1999.0994</identifier><identifier>PMID: 10732741</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cell Differentiation ; Disease Progression ; Female ; Genital system. Mammary gland ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Recurrence ; Short Communication</subject><ispartof>British journal of cancer, 2000-02, Vol.82 (4), p.760-762</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Feb 2000</rights><rights>Copyright © 2000 Cancer Research Campaign 2000 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-3337970956f0b6c1229e5d80a9c2455855046a83ec15b684780332ac7c80f4323</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374382/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374382/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1323957$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10732741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SENGUPTA, P. S</creatorcontrib><creatorcontrib>SHANKS, J. H</creatorcontrib><creatorcontrib>BUCKLEY, C. H</creatorcontrib><creatorcontrib>RYDER, W. D. J</creatorcontrib><creatorcontrib>DAVIES, J</creatorcontrib><creatorcontrib>REYNOLDS, K</creatorcontrib><creatorcontrib>SLADE, R. J</creatorcontrib><creatorcontrib>KITCHENER, H. C</creatorcontrib><creatorcontrib>JAYSON, G. C</creatorcontrib><title>Requirement for expert histopathological assessment of ovarian cancer and borderline tumours</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Differentiation</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Genital system. Mammary gland</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Recurrence</subject><subject>Short Communication</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpdkc9rFDEUx4NY7Fq9elOCiLdZX35NkosgRW2hIIjehJDJZrpZZpJtMlP0vzfTXWrrKYT3ycv3vQ9CrwisCQj-odsltyZa6zVozZ-gFRGMNkRR-RStAEA2oCmcouel7OpVg5LP0CkByajkZIV-ffc3c8h-9HHCfcrY_977POFtKFPa22mbhnQdnB2wLcWXcselHqdbm4ON2NnofMY2bnCX8sbnIUSPp3lMcy4v0Elvh-JfHs8z9PPL5x_nF83Vt6-X55-uGsdbPjWMMaklaNH20LWOUKq92Ciw2lEuhBICeGsV846IrlVcKmCMWiedgp4zys7Qx0Pf_dyNfuNqxmwHs89htPmPSTaYx5UYtuY63RrKJGdqafD-2CCnm9mXyYyhOD8MNvo0F1PDSSkFq-Db_8BdHTTW4UxNrRUnABVaHyCXUynZ9_dJCJjFmlmsmcWaWazVB28e5n-AHzRV4N0RsKW66HPdeij_uLoDLWTFXh-waKc5-_t62-q7f_4CRGCq3A</recordid><startdate>20000201</startdate><enddate>20000201</enddate><creator>SENGUPTA, P. S</creator><creator>SHANKS, J. H</creator><creator>BUCKLEY, C. H</creator><creator>RYDER, W. D. J</creator><creator>DAVIES, J</creator><creator>REYNOLDS, K</creator><creator>SLADE, R. J</creator><creator>KITCHENER, H. C</creator><creator>JAYSON, G. C</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20000201</creationdate><title>Requirement for expert histopathological assessment of ovarian cancer and borderline tumours</title><author>SENGUPTA, P. S ; SHANKS, J. H ; BUCKLEY, C. H ; RYDER, W. D. J ; DAVIES, J ; REYNOLDS, K ; SLADE, R. J ; KITCHENER, H. C ; JAYSON, G. C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-3337970956f0b6c1229e5d80a9c2455855046a83ec15b684780332ac7c80f4323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Differentiation</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Genital system. Mammary gland</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Recurrence</topic><topic>Short Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SENGUPTA, P. S</creatorcontrib><creatorcontrib>SHANKS, J. H</creatorcontrib><creatorcontrib>BUCKLEY, C. H</creatorcontrib><creatorcontrib>RYDER, W. D. J</creatorcontrib><creatorcontrib>DAVIES, J</creatorcontrib><creatorcontrib>REYNOLDS, K</creatorcontrib><creatorcontrib>SLADE, R. J</creatorcontrib><creatorcontrib>KITCHENER, H. C</creatorcontrib><creatorcontrib>JAYSON, G. C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SENGUPTA, P. S</au><au>SHANKS, J. H</au><au>BUCKLEY, C. H</au><au>RYDER, W. D. J</au><au>DAVIES, J</au><au>REYNOLDS, K</au><au>SLADE, R. J</au><au>KITCHENER, H. C</au><au>JAYSON, G. C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Requirement for expert histopathological assessment of ovarian cancer and borderline tumours</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>2000-02-01</date><risdate>2000</risdate><volume>82</volume><issue>4</issue><spage>760</spage><epage>762</epage><pages>760-762</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>10732741</pmid><doi>10.1054/bjoc.1999.0994</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2000-02, Vol.82 (4), p.760-762
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374382
source PubMed Central
subjects Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Differentiation
Disease Progression
Female
Genital system. Mammary gland
Humans
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Middle Aged
Neoplasm Staging
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Recurrence
Short Communication
title Requirement for expert histopathological assessment of ovarian cancer and borderline tumours
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A33%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Requirement%20for%20expert%20histopathological%20assessment%20of%20ovarian%20cancer%20and%20borderline%20tumours&rft.jtitle=British%20journal%20of%20cancer&rft.au=SENGUPTA,%20P.%20S&rft.date=2000-02-01&rft.volume=82&rft.issue=4&rft.spage=760&rft.epage=762&rft.pages=760-762&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.1999.0994&rft_dat=%3Cproquest_pubme%3E998619201%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-3337970956f0b6c1229e5d80a9c2455855046a83ec15b684780332ac7c80f4323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=229984100&rft_id=info:pmid/10732741&rfr_iscdi=true